Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC).

被引：0

作者：

Cassidy, J.

Bjarnason, G. A.

Hickish, T.

Topham, C.

Provencio, M.

Bodoky, G.

Landherr, L.

Koralewski, P.

Lopez-Vivanco, G.

Said, G.

机构：

[1] Beatson Oncol Ctr, Glasgow, Lanark, Scotland

[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

[3] Poole Hosp, Poole, Dorset, England

[4] Bournemouth Hosp, Bournemouth, Dorset, England

[5] Royal Surrey Cty Hosp, Guildford, Surrey, England

[6] Clin Puerta Hierro, Madrid, Spain

[7] St Laszlo Hosp, Budapest, Hungary

[8] Uzsoki St Hosp, Budapest, Hungary

[9] Rydgyier Mem Hosp, Krakow, Poland

[10] Hosp Cruces, Baracaldo, Spain

[11] Hop Bicetre, Le Kremlin Bicetre, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3507

引用

页码：147S / 147S

页数：1